Clinical

Consistent across age, sex, and race, BMI closely mirrored body fat–based obesity in nearly all US youth with BMI-defined obesity (BDO).

Panelists discuss how mineralocorticoid receptor antagonists (MRAs) remain underutilized despite being foundational therapy for heart failure with reduced ejection fraction due to clinician fears of hyperkalemia and renal dysfunction, while new nonsteroidal MRAs like finerenone show promise across the ejection fraction spectrum with potentially improved adverse effect profiles, though questions remain about their incremental benefit over traditional steroidal MRAs given their substantially higher cost.

Panelists discuss how GLP-1 receptor agonists show promising benefits for patients with HFpEF, particularly those with obesity-related disease, through significant weight loss and improved functional capacity, while their role in HFrEF remains more cautious due to concerns about increased heart rate and potential arrhythmic risks, though observational data suggest additive benefits when combined with SGLT2 inhibitors.

Panelists discuss how understanding and managing the full range of schizophrenia symptoms is key to improving long-term patient outcomes.

Panelists discuss how schizophrenia’s immense personal and financial burden calls for early, integrated, and sustained care strategies.

Panelists discuss how: clinical inertia, patient apathy, and the asymptomatic nature of high cholesterol all contribute to undertreatment and poor outcomes.

Panelists discuss how: LDL-C control remains a national crisis, with many patients not on therapy or failing to reach target levels despite the availability of effective treatments.

Experts discuss how topical therapies effectively manage atopic dermatitis in pediatric patients, enhancing outcomes and addressing unique challenges.

Innovative payer approaches and holistic support could help expand GLP-1 use and improve obesity care outcomes, experts claimed.

Comparable overall survival and distant recurrence outcomes make stereotactic body radiation a feasible alternative.

Rocatinlimab shows real-world promise for moderate to severe AD, enhancing treatment efficacy and reducing steroid reliance, explains Emma Guttman-Yassky, MD, PhD.

Aggressive lifestyle and risk factor control after ablation significantly lowers atrial fibrillation recurrence and improves heart health.

Guideline adherence in treating acute lymphoblastic leukemia (ALL) enhances health care resource utilization, especially for adolescent and young adult patients.

Panelists discuss how CNS-active EGFR TKIs are improving intracranial outcomes and influencing treatment selection in NSCLC.

Panelists discuss how new dual-targeting agents and TKIs are redefining treatment approaches in EGFR-positive NSCLC.

Experts at AMCP Nexus 2025 highlighted how real-world data can improve CAR T-cell therapy access and outcomes.

Increasing respiratory syncytial virus (RSV) vaccination among older adults could prevent up to 1600 deaths and 20,000 hospitalizations over 5 years.

Brigid Groves, PharmD, MS, discusses the importance of using trustworthy sources so that pharmacists can support communities with accurate information.

The antiretroviral (ART) regimen Biktarvy showed higher 1-year ART persistence and lower switch rates among people with HIV.

Symptoms of dry eye improved when patients in Canada used reproxalap compared with a placebo dose.

Panelists discuss how real-world outcomes inform patient conversations and support shared decision-making for third-line metastatic colorectal cancer therapies.

Panelists discuss how RWE helps guide sequencing choices when head-to-head trial data are lacking in third-line metastatic colorectal cancer.

Posters presented at AMCP Nexus 2025 found especially low oral HIV PrEP uptake among transgender individuals and those facing insurance challenges.

Panelists discuss how the treatment landscape has evolved from limited options to include hypomethylating agents and venetoclax combinations, with emerging oral formulations promising greater accessibility while requiring careful consideration of patient selection and toxicity management.

Panelists discuss how prescription digital therapeutics differ from traditional pharmaceuticals by following FDA medical device approval pathways focused on clinical performance and safety rather than chemistry and manufacturing while offering potential economic value by extending behavioral health capacity to underserved populations, especially in rural areas with limited mental health professionals.